[go: up one dir, main page]

EP2611941A4 - Gene signatures for cancer diagnosis and prognosis - Google Patents

Gene signatures for cancer diagnosis and prognosis

Info

Publication number
EP2611941A4
EP2611941A4 EP11822498.9A EP11822498A EP2611941A4 EP 2611941 A4 EP2611941 A4 EP 2611941A4 EP 11822498 A EP11822498 A EP 11822498A EP 2611941 A4 EP2611941 A4 EP 2611941A4
Authority
EP
European Patent Office
Prior art keywords
prognosis
cancer diagnosis
gene signatures
biomarkers
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11822498.9A
Other languages
German (de)
French (fr)
Other versions
EP2611941A2 (en
Inventor
Steven Stone
Alexander Gutin
Susanne Wagner
Julia Reid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myriad Genetics Inc
Original Assignee
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc filed Critical Myriad Genetics Inc
Publication of EP2611941A2 publication Critical patent/EP2611941A2/en
Publication of EP2611941A4 publication Critical patent/EP2611941A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Biomarkers and methods using the biomarkers for molecular detection and classification of disease and, particularly, molecular markers for cancer diagnosis and prognosis and methods of use thereof are provided.
EP11822498.9A 2010-08-30 2011-08-30 Gene signatures for cancer diagnosis and prognosis Withdrawn EP2611941A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37822010P 2010-08-30 2010-08-30
US40779110P 2010-10-28 2010-10-28
PCT/US2011/049760 WO2012030840A2 (en) 2010-08-30 2011-08-30 Gene signatures for cancer diagnosis and prognosis

Publications (2)

Publication Number Publication Date
EP2611941A2 EP2611941A2 (en) 2013-07-10
EP2611941A4 true EP2611941A4 (en) 2014-01-22

Family

ID=45773478

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11822498.9A Withdrawn EP2611941A4 (en) 2010-08-30 2011-08-30 Gene signatures for cancer diagnosis and prognosis

Country Status (4)

Country Link
US (2) US9605319B2 (en)
EP (1) EP2611941A4 (en)
CA (1) CA2809829A1 (en)
WO (1) WO2012030840A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2294216A4 (en) 2008-05-14 2011-11-23 Dermtech Int Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
CA2804391A1 (en) 2010-07-07 2012-01-12 Myriad Genetics, Inc. Gene signatures for cancer prognosis
EP2611941A4 (en) 2010-08-30 2014-01-22 Myriad Genetics Inc Gene signatures for cancer diagnosis and prognosis
CA2845568A1 (en) * 2011-08-19 2013-02-28 Myriad Genetics, Inc. Gene signatures for lung cancer prognosis and therapy selection
US9798918B2 (en) 2012-10-05 2017-10-24 Cireca Theranostics, Llc Method and system for analyzing biological specimens by spectral imaging
EP2920322B1 (en) * 2012-11-16 2023-01-11 Myriad Genetics, Inc. Gene signatures for cancer prognosis
JP2016515800A (en) * 2013-02-21 2016-06-02 ミリアド・ジェネティックス・インコーポレイテッド Gene signatures for prognosis and treatment selection of lung cancer
EP2976735A4 (en) * 2013-03-19 2016-12-14 Cireca Theranostics Llc Method and system for analyzing biological specimens by spectral imaging
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
WO2016179043A1 (en) 2015-05-01 2016-11-10 Dermtech, Inc. Non-invasive skin collection system
WO2015175692A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
NZ730124A (en) 2014-09-19 2023-05-26 Univ College Dublin Nat Univ Ireland Dublin A method of predicting risk of recurrence of cancer
WO2016118527A1 (en) * 2015-01-20 2016-07-28 Nantomics, Llc Systems and methods for response prediction to chemotherapy in high grade bladder cancer
ES2861316T3 (en) * 2015-05-29 2021-10-06 Koninklijke Philips Nv Methods to predict prostate cancer
WO2018212192A1 (en) * 2017-05-18 2018-11-22 京都府公立大学法人 Method and marker for estimating prognosis and/or metastasis potential of cancer
US12026683B2 (en) * 2017-06-30 2024-07-02 Intuit Inc. System and method for risk assessment of a third party application for controlling competitive migration
EP3752645A4 (en) 2018-02-14 2022-04-13 Dermtech, Inc. NEW GENE CLASSIFIERS AND THEIR USES IN NON-MELANOMA SKIN CANCERS
WO2020010305A1 (en) * 2018-07-05 2020-01-09 The Board Of Regents Of The University Of Oklahoma Gene signatures for cancer characterization and methods of use
WO2020163639A1 (en) * 2019-02-07 2020-08-13 University Of Florida Research Foundation, Incorporated Methods for targeted treatment and prediction of patient survival in cancer
EP3948290A4 (en) 2019-03-26 2023-08-09 Dermtech, Inc. NOVEL GENE CLASSIFIERS AND THEIR USES IN SKIN CANCER
CN117265114A (en) * 2023-10-13 2023-12-22 青岛瑞思德医学检验实验室有限公司 Bladder cancer detection kit and detection method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010080933A1 (en) * 2009-01-07 2010-07-15 Myriad Genetics, Inc Cancer biomarkers
WO2012006447A2 (en) * 2010-07-07 2012-01-12 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2012122626A1 (en) * 2011-03-14 2012-09-20 National Research Council Of Canada Prognostic marker sets for prostate cancer

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993388A (en) 1997-07-01 1999-11-30 Kattan; Michael W. Nomograms to aid in the treatment of prostatic cancer
US6409664B1 (en) 1997-07-01 2002-06-25 Michael W. Kattan Nomograms to aid in the treatment of prostatic cancer
CA2359816C (en) 1999-01-06 2010-08-03 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
EP2241636A1 (en) 2002-03-13 2010-10-20 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
US6809118B2 (en) 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
EP1422526A1 (en) 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
DE602004017426D1 (en) 2003-02-20 2008-12-11 Genomic Health Inc USE OF INTRONIC RNA SEQUENCES FOR THE QUANTIFICATION OF GENE EXPRESSION
WO2004111603A2 (en) 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
ES2787475T3 (en) 2003-06-24 2020-10-16 Genomic Health Inc Prediction of probability of cancer recurrence
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
WO2005059109A2 (en) 2003-12-15 2005-06-30 The Regents Of The University Of California Molecular signature of the pten tumor suppressor
US7871769B2 (en) 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2005106043A2 (en) 2004-04-23 2005-11-10 Exagen Diagnostics, Inc. Breast cancer gene expression biomarkers
US20090297500A1 (en) 2004-08-10 2009-12-03 Oncotherapy Science, Inc. NON-SMALL CELL LUNG CANCER-RELATED GENE, ANLN, AND ITS INTERACTION WITH RhoA
JP4939425B2 (en) 2004-11-05 2012-05-23 ジェノミック ヘルス， インコーポレイテッド Molecular indicators of prognosis and prediction of treatment response in breast cancer
PL1836629T3 (en) 2004-11-05 2020-06-15 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
US20070059720A9 (en) * 2004-12-06 2007-03-15 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients
WO2006091776A2 (en) 2005-02-25 2006-08-31 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
US20080275652A1 (en) 2005-05-13 2008-11-06 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
WO2006119593A1 (en) 2005-05-13 2006-11-16 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
GB0519405D0 (en) 2005-09-23 2005-11-02 Univ Aberdeen Cancer therapy prognosis and target
WO2007067500A2 (en) 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
WO2007067672A2 (en) 2005-12-06 2007-06-14 Baylor College Of Medicine Method to predict systemic progression in prostate cancer patients
WO2007070621A2 (en) 2005-12-13 2007-06-21 Children's Medical Center Corporation Prognosis indicators for solid human tumors
NZ593228A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (inhba) for colorectal cancer prognosis
US7914988B1 (en) 2006-03-31 2011-03-29 Illumina, Inc. Gene expression profiles to predict relapse of prostate cancer
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
AT504702A1 (en) 2006-12-22 2008-07-15 Arc Austrian Res Centers Gmbh SET OF TUMOR MARKERS
EP2121988B1 (en) 2007-02-23 2014-12-17 bioTheranostics, Inc. Prostate cancer survival and recurrence
EP2121738A2 (en) 2007-02-26 2009-11-25 Oxford Genome Sciences (UK) Limited Proteins
EP2140020A2 (en) 2007-03-15 2010-01-06 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2009032915A2 (en) 2007-09-06 2009-03-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Arrays, kits and cancer characterization methods
NZ562237A (en) 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
EP2568053B1 (en) 2008-05-12 2014-04-16 Genomic Health, Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
US20100184063A1 (en) 2008-05-14 2010-07-22 Ming-Sound Tsao Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
EP2469440A3 (en) 2008-06-16 2014-01-01 Sividon Diagnostics GmbH Molecular markers for cancer prognosis
US20110166838A1 (en) 2008-06-16 2011-07-07 Sividon Diagnostics Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
MX2010014280A (en) 2008-06-26 2011-05-23 Dana Farber Cancer Inst Inc Signatures and determinants associated with metastasis methods of use thereof.
WO2010037735A1 (en) 2008-10-01 2010-04-08 Noviogendix Research B.V. Molecular markers in prostate cancer
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
WO2010096627A1 (en) 2009-02-20 2010-08-26 Lisanti Michael P Therapeutics and methods for treating neoplastic diseases comprising determining the level of caveolin-1 and/or caveolin-2 in a stromal cell sample
US20120190565A1 (en) 2009-02-20 2012-07-26 Pangea Biosciences, Inc. Method Of Diagnosis Or Prognosis Of A Neoplasm Comprising Determining The Level Of Expression Of A Protein In Stromal Cells Adjacent To The Neoplasm
EP2241634A1 (en) 2009-04-16 2010-10-20 Université Libre de Bruxelles Diagnostic method and tools to predict the effiacy of targeted agents against IGF-1 pathway activation in cancer
JP2012525159A (en) 2009-05-01 2012-10-22 ジェノミック ヘルス， インコーポレイテッド Gene expression profile algorithms and trials in colorectal cancer recurrence and possible response to chemotherapy
EP3739060A1 (en) 2009-11-23 2020-11-18 Genomic Health, Inc. Methods to predict clinical outcome of cancer
US20130058924A1 (en) 2010-02-05 2013-03-07 Myriad Genetics, Incorporated Hypoxia-related gene signatures for cancer classification
WO2012012225A2 (en) 2010-07-22 2012-01-26 Mayo Foundation For Medical Education And Research Predicting cancer outcome
JP2013532482A (en) 2010-07-27 2013-08-19 ジェノミック ヘルス， インコーポレイテッド Methods for quantifying prostate cancer prognosis using gene expression
EP2611941A4 (en) 2010-08-30 2014-01-22 Myriad Genetics Inc Gene signatures for cancer diagnosis and prognosis
US20140162887A1 (en) 2011-02-04 2014-06-12 Bioarray Therapeutics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
JP2014509868A (en) 2011-03-26 2014-04-24 オレゴン ヘルス アンド サイエンス ユニバーシティー Gene expression predictors for cancer prognosis
WO2012152800A1 (en) 2011-05-12 2012-11-15 Noviogendix Research B.V. Molecular markers in prostate cancer
US20140073535A1 (en) 2011-05-12 2014-03-13 Noviogendix Research B.V. Molecular markers in prostate cancer
EP2920322B1 (en) 2012-11-16 2023-01-11 Myriad Genetics, Inc. Gene signatures for cancer prognosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010080933A1 (en) * 2009-01-07 2010-07-15 Myriad Genetics, Inc Cancer biomarkers
WO2012006447A2 (en) * 2010-07-07 2012-01-12 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2012122626A1 (en) * 2011-03-14 2012-09-20 National Research Council Of Canada Prognostic marker sets for prostate cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BIBIKOVA ET AL: "Expression signatures that correlated with Gleason score and relapse in prostate cancer", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 89, no. 6, 12 May 2007 (2007-05-12), pages 666 - 672, XP022077660, ISSN: 0888-7543, DOI: 10.1016/J.YGENO.2007.02.005 *
JACK CUZICK: "Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study", THE LANCET, vol. 12, 1 March 2011 (2011-03-01), pages 245 - 255, XP055046202, DOI: 10.1016/S1470- *
LIU JIANGANG ET AL: "Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data", BMC MEDICAL GENOMICS, BIOMED CENTRAL LTD, LONDON UK, vol. 1, no. 1, 11 September 2008 (2008-09-11), pages 39, XP021045831, ISSN: 1755-8794, DOI: 10.1186/1755-8794-1-39 *
MARK J BERESFORD1 ET AL: "Measuring proliferation in breast cancer: practicalities and applications", BREAST CANCER RESEARCH, 30 November 2006 (2006-11-30), XP055025886, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1797032/pdf/bcr1618.pdf> [retrieved on 20120427], DOI: 10.1186/bcr1618) *
MICHAEL L WHITFIELD ET AL: "Identification of Genes Periodically Expressed in the Human Cell Cycle and Their Expression in Tumors", MOLECULAR BIOLOGY OF THE CELL, vol. 13, no. 6, 1 January 2002 (2002-01-01), pages 1977 - 2000, XP055093733, DOI: 10.1091/mbc.02-02-0030 *
MOSLEY JONATHAN D ET AL: "Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists", BMC MEDICAL GENOMICS, BIOMED CENTRAL LTD, LONDON UK, vol. 1, no. 1, 25 April 2008 (2008-04-25), pages 11, XP021040894, ISSN: 1755-8794 *
QUINN D I ET AL: "Molecular markers of prostate cancer outcome", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 41, no. 6, 1 April 2005 (2005-04-01), pages 858 - 887, XP027785727, ISSN: 0959-8049, [retrieved on 20050401] *
SIMON R: "Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 89, no. 9, 1 January 2003 (2003-01-01), pages 1599 - 1604, XP002661447, ISSN: 0007-0920, [retrieved on 20031028], DOI: 10.1038/SJ.BJC.6601326 *
WANG L ET AL: "Gene networks and microRNAs implicated in aggressive prostate cancer", CANCER RESEARCH, AACR, US PHILADELPHIA, PA, vol. 69, no. 24, 15 December 2009 (2009-12-15), pages 9490 - 9497, XP002716332, ISSN: 1538-7445, [retrieved on 20091208], DOI: 10.1158/0008-5472.CAN-09-2183 *

Also Published As

Publication number Publication date
WO2012030840A9 (en) 2012-06-14
EP2611941A2 (en) 2013-07-10
US9605319B2 (en) 2017-03-28
US20170096712A1 (en) 2017-04-06
CA2809829A1 (en) 2012-03-08
WO2012030840A2 (en) 2012-03-08
US20130302242A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
EP2611941A4 (en) Gene signatures for cancer diagnosis and prognosis
WO2012006447A3 (en) Gene signatures for cancer prognosis
WO2012021887A3 (en) Biomarkers for the early detection of breast cancer
WO2011097509A3 (en) Hypoxia-related gene signatures for cancer classification
WO2012047618A3 (en) Mesothelioma biomarkers and uses thereof
IL233098A (en) Cancer Detection and Prognosis Methods and Survival Probabilities and Biomarkers Based on Their Use
WO2010009337A3 (en) Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
WO2013028554A3 (en) Gene signatures for lung cancer prognosis and therapy selection
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
EP2668296A2 (en) Colon cancer gene expression signatures and methods of use
PH12014500063A1 (en) Methods and nucleic acids for determining the prognosis of a cancer subject
MX2013000917A (en) Methods of detecting diseases or conditions using phagocytic cells.
MX2013000502A (en) Methods and kits for the diagnosis of prostate cancer.
WO2014071358A3 (en) Novel ntrk1 fusion molecules and uses thereof
WO2012061515A3 (en) Methods of classifying human subjects with regard to cancer prognosis
WO2012075069A3 (en) Signatures and determinants associated with cancer and methods of use thereof
WO2011112845A3 (en) Methods and compositions related to a multi-methylation assay to predict patient outcome
WO2011106709A3 (en) Epithelial biomarkers for cancer prognosis
EP4202441A3 (en) Gene expression profile in macrophages for the diagnosis of cancer
EP3385717A3 (en) Methods of detecting prostate cancer
EP2988131A4 (en) Genetic marker for early breast cancer prognosis prediction and diagnosis, and use thereof
NZ708027A (en) Fam19a4 and hsa-mir124-2, molecular diagnostic markers for hpv-induced invasive cancers and their high-grade precursor lesions
WO2013057581A3 (en) Composite biomarkers for non-invasive screening, diagnosis and prognosis of colorectal cancer
WO2013028807A3 (en) Renal cell carcinoma biomarkers and uses thereof
WO2013124738A3 (en) Methods and biomarkers for detection and prognosis of cervical cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130321

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20140107

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/574 20060101ALI20131219BHEP

Ipc: C12Q 1/68 20060101AFI20131219BHEP

Ipc: C12N 15/11 20060101ALI20131219BHEP

Ipc: G06F 19/10 20110101ALI20131219BHEP

17Q First examination report despatched

Effective date: 20160603

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20171017